Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Key Inclusion Criteria: * Documented diagnosis of B-cell CLL, according to International Workshop on Chronic Lymphocytic Leukemia 2008 * Presence of 17p deletion in CLL cells as demonstrated by fluorescence in-situ hybridization (FISH) testing * No prior therapy for CLL other than corticosteroids for disease complications * CLL that warrants treatment * Presence of measurable lymphadenopathy * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 Key Exclusion Criteria: * Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation) * Known presence of myelodysplastic syndrome * History of a non-CLL malignancy except for the following: * the malignancy has been in remission without treatment for ≥ 5 years prior to enrollment, or * carcinoma in situ of the cervix, or * adequately treated basal or squamous cell skin cancer or other localized non-melanoma skin cancer, or * asymptomatic prostate cancer without known metastatic disease and with no current requirement for therapy or requiring only hormonal therapy and with normal prostate specific antigen for ≥ 1 year prior to enrollment, or * ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone, or * other adequately treated Stage 1 or 2 cancer currently in complete remission * Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment * Ongoing liver injury * History of noninfectious pneumonitis * Ongoing inflammatory bowel disease * History of prior allogeneic bone marrow progenitor cell or solid organ transplantation * Ongoing immunosuppressive therapy other than corticosteroids * Received last dose of study drug on another therapeutic clinical trial within 30 days prior to enrollment * Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, electrocardiogram (ECG) finding, or laboratory abnormality Note: Other protocol defined Inclusion/Exclusion criteria may apply.